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Abstract 
In order to eliminate measles in Morocco, a mass vaccination 
campaign targeting children aged from 9 months to14 years was conducted 
on May-June 2008. The vaccination coverage was estimated to be 99%. This 
study aims to assess the impact of the measles mass vaccination campaign on 
measles incidence based on sensitive surveillance system. For this purpose, a 
laboratory case-based surveillance was set up during 2010. Epidemiological 
definition of suspected measles cases was fixed. Specimens were collected 
through all primary health centers and hospitals at national level and 
suspected cases were confirmed by serological tests. Measles strains isolated 
during outbreaks were genotyped. The performance of the surveillance 
system was evaluated according to the World Health Organization indicators. 
The incidence was calculated based on the epidemiological surveillance data, 
and compared to the World Health Organization incidence, which is 1 case 
per million per year. 1214 suspected cases were notified and 1083 measles 
samples were analyzed and 45 % (491/1083) were serologically confirmed 
and 115 cases were confirmed by epidemiological linkage. Molecular 
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epidemiology shows that genotype D4 is endemic since 2008. The WHO 
indicators show that the sensitivity of surveillance system is low. Despite this 
weak sensitivity, epidemiological data show that measles incidence is higher 
than that recommended by WHO, and reached 19.18/1 000 000. In 
conclusions, Measles mass campaign did not reach the goal expected. A 
second mass campaign should be planned in the near future to eliminate the 
disease in the country. 
 
Keywords: Measles elimination, mass campaign, epidemiology, laboratory 
confirmation/genotyping, Morocco  
 
Introduction 
Measles is one of the most contagious human diseases caused by 
Measles virus (MeV), a member of the family Paramyxoviridae, genus 
Morbillivirus. It can induce complications such as pneumonia, encephalitis, 
and death, especially among children under 5 years of age, under adverse 
conditions. In 2008, 164 000 measles deaths globally were reported 
worldwide, of which 95% occurred in countries with low-income and weak 
health infrastructures (Ciofidegliatti et al., 2006; Wichmann, 2009; Sternfeld 
et al., 2010). However, measles can be prevented with efficient vaccination 
programmes, aiming to reach the goal of its elimination ( Adetunji, Macklin, 
Patel, & Kinsinger, 2003; Moss & Griffin, 2006; Chang et al., 2010).  
WHO has established a global strategic plan for measles elimination, 
based on a theoretical target of maintaining a herd-immunity threshold of 
95% according to mathematical models. In practice, to assess the progress 
towards measles elimination, WHO proposed three main indicators: 1°) 
achieving and maintaining annual vaccination coverage of more than 95% 
with 2 measles doses in all districts in order to interrupt the endemic measles 
transmission 2°) implementing sensitive surveillance including a dynamic 
laboratory case-based investigation with the aims  to ensure the detection of 
measles virus and 3°) reaching and maintaining a low incidence, set at less 
than one case per 1 million inhabitants per year (WHO-WPRO, 2010). 
The sensitivity of the surveillance system is assessed by WHO 
indicators namely the reporting rate, the proportion of provinces reporting 
non-measles cases per 100.000 population, the proportion of measles cases 
investigated within 48h, and the proportion of laboratory confirmation for 
sporadic cases and outbreaks (WHO, 2009).  
 In Morocco, measles vaccine (MV) was introduced in 1981. The 
number of cases reported, declined from 120 000 registered annually before 
the introduction of measles vaccine to 4 216 in 1984. However, there was an 
increase again in 1987, when 26 621 cases of measles were reported (MoH-
Morocco/WHO, 2005). Consequently, the government of Morocco launched 
European Scientific Journal   May 2014  edition vol.10, No.15   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
229 
the National Immunization Days to increase vaccination coverage which 
evolved from 73% in 1987 to more than 90% since 1996 (WHO/Morocco, 
2008). In 1997, Morocco joined the WHO/EMRO Measles elimination 
program and continued to improve the vaccination coverage of one dose 
vaccine at 9 months (MoH-Morocco, 2010).  
 Based on the one-dose vaccination strategy maintained for 23 years, 
measles remained an endemic disease in Morocco with epidemic cycles that 
occurs every 4 to 5 years. The number of the annually reported cases ranged 
from 1 324 cases in 1996 to 11 000 cases in 2003 with the highest incidence 
was among children aged 5 to 9 years. 
 In response to the WHO recommendations, a second dose of MV was 
introduced in 2003 and covered all children at school entry (6 years old) 
(MoH-Morocco/WHO, 2005; MoH-Morocco, 2009). The introduction of the 
second dose of measles vaccine and the evolution of reported measles cases 
shows a significant decrease in the following three years. The annual 
reported measles cases decreased from 10 841 in 2003 to 1 217 in 2006 but 
in 2007, measles cases notification increased again and reached 2248 cases 
(figure 1).  
 
Figure 1: Reported Measles cases and vaccination coverage in Morocco by year, 1982-2008 
(MR: Measles/Rubella Vaccine; MV: Measles vaccine). 
 
Outbreaks investigated in Morocco before September 2008 were 
associated with imported genotype as D7, B3.2  (Alla et al., 2006; WHO, 
2006) and D8 (unpublished data) which became endemic strains in 2007 and 
2008 as the susceptible population was high enough to maintain the chain of 
transmission.  
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In order to reduce measles-susceptible population and to interrupt the 
endemic chain of transmission, a mass vaccination campaign (MVC) with 
Measles-Rubella (MR) vaccine was organized in May-June 2008 and 
targeted 3 547 548 children aged between 9 months and 14 years with a 
focus on hard-to-reach population (MoH-Morocco/DP, 2008). In this 
strategy, the ministry of health (MoH) had excluded children who received a 
second dose from 2003 till 2008. The immunization coverage registered was 
estimated to be 99% (WHO-EMRO, 2010). Moreover, for the purpose to 
monitor the incidence of confirmed measles cases and document the 
interruption of measles endemic transmission after the mass campaign, a 
laboratory case-based surveillance was set up at the national level on 2010 
(MoH-Morocco, 2009).  
Based on the assessment of the sensitivity of the surveillance system 
and on laboratory case based surveillance, this review will assess the impact 
of the mass campaign on measles endemic transmission in Morocco with the 
aim of reaching the elimination goal.  
 
Methodology: 
1- Establishment of Laboratory case based surveillance  
Measles is notifiable infectious disease in Morocco. In 2002, the 
MoH implemented laboratory confirmation, initially focused on outbreaks 
investigation by confirming 5 to 10 cases per outbreak. Sentinel laboratory 
surveillance was established in 2007 to monitor sporadic measles cases in 
five provinces and all outbreaks at the national level. In 2010, after the mass 
campaign, the case based surveillance was set up at the national level and 
included 69 provinces, 2600 primary health centers, 16 regional hospitals 
and 68 provincial hospitals. The population was estimated to 31 894 000 
(HCP, 2010). 
Specimen were collected from all suspected measles cases according 
to WHO definition; including any person with,  fever, a maculopapular rash, 
and either cough, coryza or conjunctivitis, or any person suspected by a 
clinician  
- Specimen collection 
During 2010, specimens were collected from patients that met 
measles clinical case definition. All sporadic cases and five to ten cases from 
each outbreak were subject to sera or oral fluids specimen collection for 
serological confirmation using specific kits (UTM-RT Transport Medium / 
COPAN, Cat# 305 for the oral fluid and Oracol Saliva collection system / 
MMD for saliva specimen). Oral fluid specimens were recommended in case 
of difficulty to collect blood samples especially among infants less than 2 
years old. In addition to sera or oral fluid specimens, urine and 
nasopharyngeal specimens were collected for measles virus isolation and 
European Scientific Journal   May 2014  edition vol.10, No.15   ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
231 
genotyping analysis. All specimens were shipped to the National Measles 
Reference laboratory at the National Institute of Hygiene, in cold boxes with 
an investigation form including clinical and epidemiological data  
- Serological analysis 
Serum or Oral fluid was collected within 28 days of rash onset. 
Specimens were tested first for IgM specific to measles. As recommended by 
WHO, all negative samples for measles IgM were tested for rubella IgM. 
Suspected cases with negative measles laboratory results were discarded as 
non-measles cases. 
Serological confirmation was done using two commercial ELISA test 
kits provided by the WHO; the Enzygnost® Anti-Measles virus (Siemens) 
(Marburg, Germany) for serum samples and Measles IgM capture EIA 
(Microimmune Ltd) (Hounslow, UK) for oral fluid samples, performed 
according to the manufacturer’s instructions. 
The serological data of the national measles surveillance was 
analyzed according to the age group and to the vaccination status, and used 
to assess the surveillance performance and to calculate measles incidence.  
- Measles genotyping  
Measles virus was isolated from urine or throat swab samples 
collected from outbreaks within 3 and 5 days of rash onset. Virus isolation 
was performed on Vero Slam cells. 
RNA extraction was performed from positive cell culture using the 
QIAamp viral RNA mini kit (QIAGEN) (Hilden, Germany). RT-PCR 
analysis was done using primers provided by The Centers for Disease 
Control and Prevention-Atlanta-GA (CDC). MeV216 (Forward): 5’ 
TGGAGCTATGCCATGGGAGT 3’ and MeV214 (Reverse): 5’ 
TAACAATGATGGAGGGTAGG 3’ to amplify a 634-bp fragment of 
nucleoprotein coding gene, using superscript one step reverse transcription  –
PCR (cat# 210210/210212, QIAGEN) according to the manufacturer’s 
instruction.  
The PCR product was then purified using the Wizard® minicolumn. 
The purified amplicons were sequenced using the BigDye Terminator V 1.1 
kit and   analyzed on ABI PRISM 310 automatic sequencer.  
Sequence data were analyzed using Seqscape Software Version 2.5. 
Nucleotide sequences (450 pb) alignment, phylogenetic tree and molecular 
evolutionary analysis were performed using MEGA5 software (Tamura et 
al., 2011). 
 
2-Assessment of the surveillance system 
The surveillance system was evaluated based on the following WHO 
indicators: 
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a- The reporting rate, should be at least two non-measles suspected 
measles cases per 100 000 population. 
Reporting rate= number of non measles cases/ total population 
x100.000 
b- The annual measles detection should be at least one non-measles 
suspected case per 100 000 population in at least 80% of provinces (WHO, 
2001).  
Annual measles detection= number of provinces reporting at least one 
non-measles suspected case per 100 000 population / total of provinces. 
c- Measles case investigation should be done within 48 hours of 
notification for a minimum of 80% of all reported suspected measles cases.  
Measles case investigation= number of reporting cases within 48 h / 
total of reporting cases. 
d- Laboratory confirmation of at least 80% of suspected measles 
cases,  
Laboratory confirmed cases= number of laboratory confirmed cases/ 
total of cases notified. 
e- Viral detection from at least 80% of laboratory-confirmed 
outbreaks 
Viral detection of laboratory-confirmed outbreaks= number of 
confirmed outbreaks with virus isolation by Cell culture/total of outbreak 
notified.  
 
3- Determination of measles incidence  
The incidence of confirmed measles cases per 1 000 000 habitants 
after mass campaign was calculated based on laboratory data and 
epidemiological linkage. Measles incidence after the mass campaign was 
compared to the WHO indicator fixed to 1 case per million habitants for 
reaching the elimination goal.  
Incidence of measles per million of habitants = number of measles 
confirmed cases/total population. 
 Results: 
1-Laboratory case based surveillance 
During 2010, 1214 measles cases were notified. The NML received 
samples from 1104 cases, from which 1083 had specimen for serological 
analysis (930 sera and 153 oral fluid), and 192 samples for virus isolation (93 
urine and 99 throat swab). 21 specimens were inadequate for serological 
analysis. 
Among 1083 samples, 491 (45%) were IgM positive. 592 cases were 
classified as non-measles cases. All negative samples were tested for rubella 
IgM. One case was confirmed rubella IgM positive. 115 measles cases were 
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confirmed by epidemiological linkage. Thus, the incidence in the general 
population reached 19 per million inhabitants. 
According to the distribution of confirmed cases by age group, the 
most susceptible population to measles infection were age group [0-4] 
followed by the age groups [5–9], [15–19] and [20-24]. 
Furthermore, the incidence of measles per million, and by age groups, 
shows a high incidence in the age group <=4 years, 44% (47/106) of 
confirmed cases among this group were aged less than one year. The second 
high incidence was observed among the age group [5-9], followed by [15-19] 
and [20-24]. In contrast, the incidence is low in the age groups older than 35 
years (Table 1).  
Table 1: Distribution of confirmed measles cases and measles incidence by age groups, 
Morocco, 1st Jan. - 30 Dec. 2010 
Age 
groups 
(years) 
Number of 
population by age 
group (2010) 
Clinically suspect 
measles cases 
Confirmed 
measles 
cases 
Incidence 
(per Million) 
0 - 4 2903000 456 106 36,51 
5 - 9 2865000 224 88 30,72 
10 - 14 2986000 63 22 7,37 
15 - 19 3215000 118 86 26,75 
20 - 24 3106000 86 64 20,61 
25 - 29 2928000 66 52 17,76 
30 - 34 2503000 47 39 15,58 
35 - 39 2194000 24 19 8,66 
40 - 44 1877000 5 3 1,60 
>=45 7317000 15 12 1,64 
Total 31894000 1104 491 15,39 
 
Information on vaccination status was available for 358/491 
confirmed cases (73%), the overall rate of vaccinated cases was 48%, 8/172 
cases had received two doses (figure 2). 
 
Figure 2: Distribution of the laboratory confirmed measles cases by immunization status 
and by age group, Morocco, 1st Jan.-31 Dec. 2010. (The monovalent measles vaccine was 
administered for the one dose at 9 month of age and the bivalent measles/rubella vaccine for 
the second dose). 
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Virus isolation and molecular data analysis 
Phylogenetic analysis shows that all viruses isolated from cases 
reported during 2010 belong to D4 genotype and had identical N gene 
sequences. They are closely related to the WHO genotype D4 reference 
strain (MVi/Montreal.CAN/89), and to the D4 strains that were isolated in 
2008 after the mass campaign (MVi/Midelt.MAR/37.08/, GenBank 
accession numbers: FJ595981 and FJ595982). They also showed 100% 
identity with the strain MVs/Enfield.GBR/14.07/ isolated in the UK in 2007 
(GenBank accession no: EF600554) and to the D4 genotype that was isolated 
all over the world during 2007 and 2008 (Chironna et al., 2007; Rota et al., 
2011), suggesting that this virus may have been imported (figure 3). The 
sequence analysis comparison was done with 11 measles reference strains 
from GenBank (accessions numbers: HQ338080, HQ338077, HQ338078, 
HQ338073, HQ338074, HQ338075, HQ338076 and HQ338079). 
 
Figure 3: Phylogenetic analysis of measles strains collected between 1998 and 2011 based 
on the C-terminal of the N gene and were compared with the WHO reference sequences. 
The Phylogenetic tree shows the representative genotype strains identified in Morocco 
before (in Green) and after (in red) the mass campaign organized in June 2008. An unrooted 
tree is drawn after analysis using maximum parsimony. 
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Assessment of epidemiology surveillance indicators  
Based on WHO-EMRO measles elimination indicators, the 
surveillance system in Morocco reported the following results (table 2): 
Table 2: Measles surveillance indicators, Morocco, 2010. 
Indicators Target Morocco (2010) 
National reporting of non-measles 
suspected cases 
> 2/100 000 1.86/100 000 
Percentage of districts reporting ≥ 
1/100,000 non-measles suspected cases 
> 80% 88% 
Percentage of suspected cases with 
adequate investigation within 48 hours of 
notification 
> 80% 84% 
Laboratory confirmation of suspected 
measles cases 
> 80% 89% 
Viral detection from at least 80% of 
laboratory-confirmed outbreaks 
>=80% 61% 
 
Based on laboratory results, 592 suspected measles cases were 
discarded as non-measles. The incidence rate at the national level is 1.86 per 
100 000 inhabitants. 
Among 69 provinces, 61 (88%) have a rate >=1 per 100 000 
inhabitants measles cases. 
Eighty four percent 84% (922/1104) of all reported suspected measles 
cases were investigated within 48 hours of notification.  
The national measles laboratory confirmed 89% (1 083/1214) of 
reported cases.  
NML received adequate samples for viral detection from 11 
outbreaks, which represent 61% of all outbreaks (18) reported during 2010. 
 
Discussion  
The current study shows that in 2010, the performance of the 
surveillance system was adequate for only two of the elimination indicators. 
Despite the low sensitivity of the surveillance system, measles incidence 
remains higher than one measles confirmed case per 1000000 population. 
The wide distribution of confirmed measles cases and the large number of 
outbreaks confirms the circulation of the virus among a high population of 
susceptible.   
The epidemiological analysis of confirmed cases shows that all age 
groups were affected by measles. However, the incidence of measles was 
higher for age groups under 9 year and 15-24 years. For the age group under 
9 months that is not eligible for the vaccination, the current vaccination 
strategy did not protect children of getting the disease through the herd 
immunity as supposed. For the age group 17-24 years; this group had 
received only one dose of measles vaccine at 9 months, which led to the 
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accumulation of susceptibles. Indeed, the efficiency of the measles vaccine at 
9 month is only 85% (Lee & Nokes, 2001; Bauch et al., 2009).  
The children aged between 2 and 16 years, were also reported as 
susceptible to develop the disease. According to the national immunization 
strategy, this group belongs to the population that received two doses of 
measles vaccine, with an estimated coverage of 90% (MoH-Morocco/DPRF, 
n.d.). A high number of measles confirmed cases among this age group led 
us to suppose an underestimation of the population targeted by the mass 
campaign. Moreover, the fact that the population targeted by the second dose 
implemented since 2003 had been excluded during the 2008 mass campaign 
may contribute to increase measles cases among this age group. Indeed, 
WHO recommended strategy for the first mass immunization campaign 
specifies to vaccinate the target population regardless their previous 
immunization status (WHO-EURO, 2005; WHO-EMRO, 2006; WHO, 
2012).   
The group, including adults older than 25 years, has also been 
affected, but not with a high incidence, as before the introduction of measles 
vaccines in 1980 in Morocco (Bouskraoui & Braikat, n.d.), nearly all 
children contracted measles. 
Molecular characterization of measles virus shows that 83% of 
investigated outbreaks belong to the D4 genotype. Retrospective molecular 
analysis of measles cases in Morocco reported during outbreaks in 1998 and 
1999 revealed that C2 genotype was the only genotype circulating in 
Morocco (Alla et al., 2002). Later studies, conducted between 2003 and 
2005, show that multiple genotypes co-circulated; C2, D7, B3.2 and A virus 
were isolated in 2004 (Alla et al., 2006). Phylogenetic analysis suggests an 
importation from Europe and Sub Saharan African countries (WHO, 2005; 
Griffin & Oldstone, 2009; Kremer et al., 2010; Peña-Rey et al., 2010). 
Strains isolated in 2005-2006 belong to genotype D8 that was circulating in 
all Moroccan regions (unpublished data). D8 genotype was identified in 
recent study of 9 samples collected before the mass vaccination campaign, 
during outbreaks that occurred between 2007 and 2008 (unpublished data). 
D8 genotype had been circulating for more than 12 months and appeared to 
replace C2 as the endemic genotype. After the mass vaccination campaign, 
molecular characterization of the measles virus isolated during the outbreaks 
that occurred in September 2008, revealed the predominance of the genotype 
D4, which has had a worldwide distribution during the last three years 
(Chironna et al., 2007). Phylogenetic analysis shows that strains isolated in 
Morocco had sequences identical to the Enfield D4 strain (EF600554) 
isolated in England in 2007, which has been widely implicated in outbreaks 
all over the world during 2007 and 2008 especially in Europe (Kremer et al., 
2008; Peña-Rey et al., 2009; Rota et al., 2011). The isolation of viruses with 
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the identical sequences in Gibraltar supports the hypothesis of the 
importation (Nieto Vera et al., 2010). Viruses associated with outbreaks that 
occurred during 2010 in different provinces of Morocco have identical N 
gene sequences suggesting the spread of the 2008 D4 lineage. Thus, the D4 
genotype has become the endemic genotype in Morocco. 
 
Conclusion 
The results of this study show that there are still major challenges to 
reach the 2015 measles elimination goals in the country. Although vaccine 
coverage improved over time, this assessment confirms that high coverage in 
children documented by epidemiological data is inevitable to avoid the 
spread of the virus. Also, it’s necessary to maintain a high level of 
vaccination in each birth cohort to avoid new reservoirs of susceptible 
persons.  
The ministry of health has to strengthen its efforts by taking action to 
reach high population immunity by conducting sero-surveillance after each 
vaccination campaign, identify susceptible population and conduct 
supplementary immunization activities. 
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